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57) ABSTRACT 
A high calcium chemically defined animal cell culture 
medium including vitamins A and D and a fatty acid or 
its ester. The medium is particularly adapted for the 
primary or secondary culture of epithelial cells. How 
ever, the medium may be utilized for establishing and 
maintaining cell lines, in particular myelomae and hy 
bridomae. 
26 Claims, No Drawings 
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1. 
HIGH CALCIUM CHEMICALLY DEFINED 
CULTURE MEDUM 
The United States government may have rights in 
this patent because of relevant developmental work 
supported by Research Grant No. CA43278 from Na 
tional Institutes of Health. 
This is a divisional of copending application Ser. No. 
337,143, filed Apr. 12, 1989 now U.S. Pat. No. 
5,126,261, issued Jun. 30, 1992. 
BACKGROUND OF THE INVENTION 
For many years researchers have attempted to per 
fect a cell culture medium which enabled animal cells to 
proliferate in vitro. Two general types of cell culture 
medium have been developed: culture medium supple 
mented with pituitary extract or serum (Serum-Supple 
mented Medium: SSM), and chemically defined media 
without serum (Chemically Defined Medium: CDM). 
With respect to SSM, the addition of serum to the cul 
ture medium introduces a very large number of unde 
fined components. Among these are regulatory com 
pounds, that is to say compounds which regulate cell 
metabolism. Compounds such as these complicate the 
study of the regulatory mechanisms which control the 
proliferation, differentiation and longevity of animal 
cells. Moreover, in the case of industrial use of estab 
lished animal cell lines, the presence of serun or of 
other unknown or poorly defined components creates 
difficulty in purifying the one or more biological prod 
ucts produced by the cells. In addition, because many 
biological products cannot be purified, the non-defined 
composition of SSM leads to prohibitions against 
human utilization of these biological products by the 
international and national health authorities (FDA, 
Ministries of Health, and the like). 
One type of SSM which has been used extensively in 
research is "high' calcium SSM. "High' calcium me 
dium is defined as medium having greater than 0.1 mM 
calcium. Several researchers have demonstrated the 
importance of calcium in culture medium. Long term 
primary cultures of epidermal cells have been difficult 
to establish and maintain in high calcium medium. 
"Low" calcium medium is defined as medium having 
less than 0.1 mM calcium. It has been reported that in 
"low" calcium medium, although keratinocytes will 
proliferate, they neither stratify, make desmosomes, nor 
produce keratins characteristics of their terminal differ 
entiation (1). However, increasing the concentration of 
calcium in these media induces failure to proliferate, 
terminal differentiation and sloughing of all normal 
epidermal cells (2, 3, 4). In the past, a selection with 
"high' calcium medium has provided an excellent vehi 
cle for assaying for carcinogen or virally altered epider 
mal cells, as well as the factors involved in the induction 
of terminal differentiation (2, 5, 6, 7, 8). Nevertheless, 
"high" calcium SSM is inappropriate for any studies 
dependent upon concomitant proliferation and differen 
tiation such as, comparing the proliferation potential of 
normal untreated epidermal subpopulations, or for bio 
logical, toxicological, and metabolic studies which may 
be influenced by undefined components in the medium. 
To overcome the various drawbacks presented by 
cell lines established in "high" calcium SSM, various 
authors have replaced serum with hormones, electro 
lytes, and growth factors, such as, insulin, calcium and 













CDM. However, none of these media have been as 
successful as the "high' calcium SSM in establishing 
and cultivating primary and secondary cell cultures. 
The present inventors previously developed a "high' 
calcium CDM which was used to establish and cultivate 
epidermal cells from adult mice. This formulation, how 
ever, was found to be inferior to a companion "high" 
calcium SSM with regard to culture longevity (1). Ac 
cordingly, a new "high' calcium CDM is needed which 
overcomes the problems associated with "high' cal 
cium SSM and prior "high' calcium CDM. 
A new "high' calcium CDM which is superior or 
equal to "high' calcium SSM and prior "high' calcium 
CDM in establishing and cultivating animal cell offers 
many advantages over prior animal cell culture me 
dium. Among these are: 1) the long term growth and 
proliferation of freshly isolated animal cells; 2) ease of 
purifying biological products from the medium for ther 
apeutic applications; and 3) the ability to conduct meta 
bolic, toxicological, and carcinogenesis studies without 
interference by undefined factors. 
The present inventors have developed a chemically 
defined, "high' calcium animal cell culture medium. 
The inventive medium now enables researchers to in 
vestigate the influence of biological and xenobistic 
agents on the outgrowth and subsequent longterm 
maintenance of normal animal cells obtained from ex 
plants or primary cultures of dispersed cells. The de 
fined composition of the present inventive medium and 
its ability to support the growth and differentiation of 
animal cells in vitro should be useful for a number of 
studies related to carcinogenesis, toxicology, cell me 
tabolism and pharmacology, for example in a murine 
model system, that have not previously been possible. 
SUMMARY OF THE INVENTION 
The present invention is directed to a high calcium 
chemically defined animal cell culture medium. The 
medium includes, in combination, a synthetic basal me 
dium designed for animal cell culture, a retinoid such as 
vitamin A at a concentration of from about 0.01 to 
about 1.0 mg/l, vitamin D2 at a concentration of from 
about 0.01 to about 0.5 mg/l, and a fatty acid or its ester 
at a concentration of from 0.01 mg to about 1 mg/l. The 
medium is particularly adapted for the primary and 
secondary culture of epithelial cells. 
The present invention further involves a method for 
the primary culture of epithelial cells comprising incu 
bating said cells in a high calcium chemically defined 
animal cell culture medium. The preparation of such 
media is also a component of the present invention. In 
one aspect, the medium of the present invention in 
cludes: 
(a) a synthetic basal medium designed for animal cell 
culture; 
(b) retinoid such as vitamin A at a concentration of from 
about 0.01 to about 1.0mg/1. 
(c) vitamin D2 at a concentration of from about 0.01 to 
about 0.5mg/l; 
(d) a fatty acid or its ester at a concentration of from 
about 0.01 mg to about 1 mg/l; and 
(e) calcium at a concentration of from about 0.1 mM to 
about 1.4 mM. 
Preferred synthetic basal media of the present culture 
medium include MCDB-151 and SPRD-110. The reti 
noid such as vitamin A used in this medium is preferably 
at least one form of retinoid selected from the group 
consisting of retinyl acetate, retinol, retinal, retinoic 
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acid, retinyl palmitate, retinyl acetate being preferred 
(particularly at a concentration of about 0.115 mg/l). 
The vitamin D2 of the medium may be a reduction 
product of vitamin D2 such as dihydrotachysterol. The 
fatty acid of the medium is preferably one or more of 5 
arachidonic acid, palmitic acid, stearic acid, oleic acid, 
and linoleic acid. Arachidonic acid and linoleic acid are 
especially preferred (particularly at a concentration of 
0.100 mg/l). The above described medium preferably 
contains calcium at a concentration of about 1.2 mM. 
In a broad aspect the chemically defined cell culture 
medium of the present invention may be used for any 
animal cell culture but is particularly preferred for cul 
ture of primary or secondary epithelial cells. A pre 
ferred medium for these purposes may be partially sum 
marized as a medium including: 
(a) a synthetic basal medium designed for animal cell 
culture; 
(b) retinyl acetate at a concentration of from about 0.01 
to about 1.0 mg/l; 
(c) ergocalciferol at a concentration of from about 0.01 
to about 0.5 mg/l; 
(d) linoleic acid at a concentration of from 0.01 mg to 
about 1.0 mg/l; and 
(e) calcium at a concentration from about 0.1 mM to 
about 1.4 nM. 
In greater detail, the present invention involves a 
method for the primary culture of epithelial cells com 
prising incubating said cells in a a high calcium chemi 
cally defined cell culture medium, including: 
(a) a synthetic basal medium designed for animal cell 
culture; 
(b) an amino acid supplement; 
(c) a vitamin supplement; 
(d) a mineral supplement, said mineral supplement in 
cluding from about 0.1 mM to about 1.4 mM calcium; 
(e) a trace element supplement; 
(f) a growth supplement; 
(g) retinyl acetate at a concentration of from about 0.01 
to about 1.0 mg/l; 
(h) ergocalciferol at a concentration of from about 0.01 
to about 0.5 mg/l; and 
(i) linoleic acid or its ester at a concentration of from 
about 0.01 to about 1.0 mg/l. 
The medium itself and its preparation also constitute 
part of the present invention. The preferred amino acid 
supplement is MEMAAS (see exemplary material for 
definition) and is usually from about 5 to about 50 ml 
(most preferably about 20 ml) of the amino acid supple 
ment is added to each 1000 ml of the synthetic basal 
medium. The preferred vitamin supplement is MEMVS 
and from about 1 to about 30 ml (preferably about 10 
ml) of the vitamin supplement is preferably added to 
each 1000 ml of the synthetic basal medium. The pre 
ferred mineral supplement includes calcium, iron, zinc, 
magnesium and sodium each of which may be added to 
the synthetic basal medium separately. Calcium is pres 
ent in a most preferred concentration of about 1.2 mM. 
The trace element supplement preferably includes sele 
nium, manganese, silicon, molybdenum, vanadium, 
nickel and tin. The amino acid supplement, the vitamin 
supplement, the mineral supplement, the trace element 
supplement, and the growth supplement are included 
with the synthetic basal medium. A preferred synthetic 
basal medium used is SPRD-110. Preferred growth 
supplements include one or more of delipidized bovine 
serum albumin, insulin, transferrin, epidermal growth 











an antibiotic and a corticosteroid. The antibiotic pre 
ferred for use in this medium is a broad spectrum antibi 
otic such as one or both of penicillin or streptomycin, 
usually at a concentration of from about 50,000 to about 
1,000,000 units/1 and from about 50,000 to about 
1,000,000 units/1 respectively (most preferably they are 
both present at a concentration of about 100,000 
units/l). The most preferred concentration of retinyl 
acetate is about 0.115 mg/l and of ergocalciferol-about 
0.100 mg/1. The linoleic acid is present at a preferred 
concentration of about 0.100 mg/l. 
In greater detail, a preferred high calcium chemically 
defined cell culture medium of the present invention is 
one wherein about 1100 ml of said medium includes: 
(a) MCDB media-151 1000 ml; 
(b) MEM amino acid solution 20 ml; 
(c) MEM vitamin solution 10 ml; 
(d) About 130 mg of CaCl2: 
(e) About 0.4 mg of FeSO4.7H2O, 
(f) About 122 mg of MgCl2.6H2O; 
(g) About 0.86 mg of ZnSO4.7H2O; 
(h) About 3.50 mg of Na2SO4; 
(i) Trace element supplement 10 ml; 
(j) About 1.1 grams of delipidized bovine serum albu 
mln; 
(k) About 5 mg of insulin; 
(l) About 10.0 mg of transferrin; 
(m) About 120 mM glutamine; 
(n) About 5.6 mg of phosphoethanolamine; 
(o) About 2.4 mg of ethanolamine; 
(p) About 100,000 units of penicillin; 
(q) About 100,000 units of steptomycin; 
(r) About 1 mg of hydrocortisone; 
(s) About 10 micrograms of epidermal growth factor 
(t) About 0.12 mg of retinyl acetate; 
(t) About 0.1 mg of ergocalciferol; and 
(u) About 0.1 mg of linoleic Acid. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The present invention is directed toward a "high' 
calcium chemically defined cell culture medium for 
establishing and cultivating animal cells, preferably 
epithelial cells. This cell culture medium does not con 
tain serum or other undefined supplement and is suitable 
for both the primary culture of animal cells and for the 
establishment of cell lines from this primary culture or 
others. The present inventor has demonstrated that the 
addition of retinyl acetate, ergocalciferol and linoleic 
acid to a "high' calcium chemically defined media 
results in surprising and unexpected cell growth and 
differentiation. These results were superior to those 
previously observed in other "high' calcium chemi 
cally defined o serum supplemented cell culture me 
dium. 
According to one preferred embodiment, a high cal 
cium chemically defined animal cell culture medium is 
provided which includes: (a) a synthetic basal medium 
designed for animal cell culture; (b) vitamin A at a 
concentration of about 0.01 to about 1.0 mg/l; (c) vita 
min D2 at a concentration of about 0.01 to about 0.5 
mg/l; and (d) a fatty acid or its ester at a concentration 
of 0.01 to about 1 mg/l. 
The synthetic basal medium of the present invention 
may be one of several commercially available synthetic 
basal medium customarily used for the culture of animal 
cells. However, the most preferred synthetic basal me 
dium is MCDB-151 (for example, catalog No. 9061; 
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Irvine Scientific, Santa Ana, Calif.). MCDB-51 has the 
following composition: 
MDCBMEDIA 15 
MCDB 51 5 
COMPONENT ng/ 
L-Alanine 8.9 
L-Arginine HCl 210.7 
L-Asparagine.H2O 15.01 
L-Aspartic Acid 3.99 1O 
L-Cysteine HC.H2O 42.02 
L-Glutamic Acid 4. 
L-Glutarnine 87.2 
Glycine 7.5 
L-Histidine HCI.H2O 16.77 
L-Isoleucine 1.97 15 
L-Leucine 65.58 





-Threonine 9 20 
L-Tryptophan 3.06 
L-Tyrosine, 2Na.2H2O 3.92 
-Valine 35.3 
di-Biotin 0.046 
D-Ca Panothenate 0.238 
Choline Chloride 3.96 25 
Folic Acid 0.794 
-Inositol 8.02 
Niacinamide 0.0366 
Pyridoxine HCl 0.0617 
Riboflavin 0.0376 
Thiamine HC 0.0337 3O 
Vitamin B12 0.407 
Adenine HC 30,89 
DL-a-Lipoic Acid 0.06 
Putrescine 2HC 0.6 
Thymidine 0.77 
CaCl2 (anhyd) 3.33 
KC .83 35 
MgCl2.6H2O 22.0 
NaCl 7599. 
Na2HPO4 (anhyd) 283.96 
CuSO4.5H2O 0.00250 
FeSO4.7H2O 0.47 
ZnSO4.7H2O 0.863 40 
Glucose 108. 
HEPES 6600, 
Phenol Red. sodiurn salts 1,242 
Sodium Acetate.3H2O 500. 
Sodium Pyruvate 55,02 
NaHCOs 76. 45 
pH 7.4 before 
NaHCO3 
addition 
use 5% CO 
Vitamin A (retinol) is included in the inventive me- 50 
dium in concentrations of 0.01 to about 1.0 mg/l. Most 
preferably, however, vitamin A is present at a concen 
tration of about 0.115 mg/l. 
Vitamin A acid (retinoic acid) is a naturally-occur 
ring metabolite of vitamin A which possesses substan- 55 
tially the same or greater biological activity in epithelial 
cells compared with the parent compound, vitamin A 
(retinol). The term "vitamin A', for the purpose of this 
invention, includes the many other forms of retinol such 
as retinyl acetate, retinoic acid, retina and the like. 60 
Thus, any of the oxidation states of retinol, variants of 
retinol, retinoic acid, esters of retinoic acid, variants of 
retinoic acid or synthetic retinoids with biological ac 
tivity Substantially similar to retinol or retinoic acid 
may be utilized in the practice of the present invention. 65 
For example, the most preferred form of vitamin A is 
retinyl acetate. According to another preferred embodi 
ment retinyl palmitate is included in the inventive me 
dium. According to still another preferred embodiment 
retinal, the aldehyde of vitamin A, is present in the 
inventive medium. In a further preferred embodiment, 
retinoic acid is present in the inventive medium. Ac 
cordingly, vitamin A (retinol), any of its derivative 
forms, retinoic acid, any of its derivative forms or syn 
thetic retinoids with biological activity substantially 
similar to retinol or retinoic acid may be utilized in the 
practice of the present invention. 
Vitamin D2 (ergocalciferol), a form of vitamin D 
derived from vegetable sources, is present in the inven 
tive medium at a concentration of from 0.01 to about 0.5 
mg/l. Vitamin D3 (calciferol) is the physiologically 
equivalent compound derived from animal sources. 
Most preferably, vitamin D2 is present at a concentra 
tion of about 0.10 mg/l. The term "vitamin D", for the 
purpose of this invention, includes any and all vitamin 
D2 and vitamin D3 derivatives, including their hydrox 
ylated metabolites, and synthetic or naturally-derived 
compounds which possess substantial vitamin D-like 
biological activity. Thus, any of the pharmaceutically 
acceptable forms of vitamin D may be utilized in the 
practice of the present invention, for example, dihydro 
tachysterol (a reduction product of vitamin D2). How 
ever, according to the most preferred embodiment, 
ergocalciferol (vitamin D2) is included in the inventive 
medium. 
A fatty acid is present in the inventive medium at a 
concentration of from 0.01 mg to about 1.0 mg/l, and 
most preferably at a concentration of about 0.1 mg/l. 
The most preferred fatty acid is linoleic acid. It should 
be noted, however, that other fatty acids or their esters, 
for example, arachidonic acid, palmitic acid, stearic 
acid, and oleic acid may be utilized in the practice of the 
present invention. 
The chemically defined medium of the present inven 
tion is a "high' calcium medium. A "high' calcium 
medium is a medium having from about 0.1 mM to 
about 1.4 mM calcium. The media of the present inven 
tion are preferably within this range and most prefera 
bly have a calcium concentration of 1.2 mM. 
The cells cultivated in the inventive medium are 
animal cells, and are most preferably epithelial cells. 
However, cells lines, such as, hybrodomae and myelo 
mae may also be cultivated in the inventive medium. 
According to another preferred embodiment, a 
chemically defined "high" calcium animal cell culture 
medium is provided which includes: a synthetic basal 
medium designed for animal cell culture; retinyl acetate 
at a concentration of from about 0.01 to about 1.0 mg/l; 
linoleic acid at a concentration of from about 0.01 to 
about 1.0 mg/l; and ergocalciferol at a concentration of 
from about 0.1 to about 0.5 mg/l. 
According to a further preferred embodiment, a 
chemically defined cell culture medium is provided 
including: a synthetic basal medium designed for animal 
cell culture; an amino acid supplement; a vitamin sup 
plement; a mineral supplement; a trace element supple 
ment; a growth factor supplement; retinyl acetate at a 
concentration of from 0.01 to about 1.0 mg/l; ergocal 
ciferol at a concentration of from about 0.01 to about 0.5 
mg/1; and linoleic acid or its ester at a concentration of 
from about 0.01 to about 1.0 mg/1. 
An amino acid supplement is included in the inven 
tive medium. The most preferred amino acid supple 
ment is Modified Eagles Media Anino Acid Solution 
50X (MEMAAS) (for example, CAT 13-606 Whitaker, 
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According to one preferred embodiment, from about 
5 to about 50 ml of the amino acid supplement is added 
per liter to the synthetic basal medium, most preferably, 
MCDB-151. According to the most preferred embodi 
ment about 20 ml MEMAAS is added to every 1000 ml 
of the synthetic basal cell medium. It should be noted, 
however, that the amino acid supplement set forth 
above, MEMAAS, is illustrative of amino acid formula 
tions which may be used in the present invention, and 
other amino acid supplements may be utilized in the 
practice of the present invention. 
A trace element supplement is included in the inven 
tive medium. The most preferred formulation for the 
trace element supplement is provided in McKeehan, 
WL et al., In vitro, 13:399-416 (1977) (9). According to 
the most preferred embodiment, the trace element sup 
plement of the present invention is prepared according 
to the following recipe: a 1 liter stock solution is pre 
pared for each of the following trace elements in the 
following concentrations: 0.3869 g of H2SeO3/1iter 
H2O; 0.0198 g of MnCl2.4H2O/liter of water; 14.2100 
grams of Na2SiO3.9H2O/liter of H2O, 0.1236 grams of 
(NH4)6 Mo7O24.4H2O/liter H2O; 0.0585 grams of 
NH4VO3/liter H2O; 0.0131 grams of NiSO4.6H2O/liter 
of H2O; 0.0113 grams of SnCl2.2H2O/liter of 0.02N 
HCl; and then add 1 ml from each liter of the above 
stock solutions and 0.1 ml of NHCl to 92.9 ml of H2O 
to make 100 ml of trace element supplement. The final 
solution should be filtered after the pH of the final solu 
tion is adjusted to between 7 and 7.5. From 1 to about 30 
ml of trace element supplement is added to every 1000 
ml of the synthetic basal medium, most preferably the 
synthetic basal medium is, MCDB-151. According to 
the most preferred embodiment, 10 ml of trace element 
supplement is added to every 1000 ml of synthetic basal 
medium. 
A vitamin supplement is included in the inventive 
medium. The most preferred vitamin supplement of the 
present invention is Modified Eagles Media Vitamin 
Solution (MEMVS) (for example, 100x, CAT. 13-607, 
Whitaker, M.A. Bioproducts). Following is the formu 
lation for Eagles Modified Media Vitamin Solution: 
VITAMENS ng/ 
D.Ca.Pantothenate 100.00 
Choline Chioide 100.00 






















According to one preferred embodiment, from about 
1 to about 30 ml of the vitamin supplement is added to 
about every 1000 ml of the synthetic basal medium. 
However, most preferably, about 10 ml of the vitamin 
supplement is added to every 1000 ml of the synthetic 
basal medium. The vitamin supplement formulation set 
forth above is illustrative of vitamin supplements which 
can be utilized in the practice of the present invention. 
A mineral supplement is included in the inventive 
medium. Preferably, the mineral supplement includes 
calcium, iron, zinc, magnesium and sodium. According 
to the most preferred embodiment. the above minerals 
are present as the following salts: CaCl2, FeSO4.7H2O; 
MgCl2.6H2O, ZnSO4.7H2O; Na2SO4.CaCl2 is prefera 
bly added to the synthetic basal medium in an amount 
from about 13.0 to about 150 mg l, and most preferably 
in an amount of about 130 mg/l, FeSO4.7H2O is prefer 
ably added to the synthetic basal medium in an amount 
from about 0.04 to about 1.2 mg/l, and most preferably 
in an amount of about 0.4 mg/l. MgCl2.6H2O is prefera 
bly added to the synthetic basal medium in an amount of 
from about 12.0 to about 244.0 mg/l, and most prefera 
bly in an amount of about 122.0 mg l. ZnSO4.7H2O is 
added to the basal medium in an amount of from about 
0.08 to about 1.7 mg, and most preferably in an amount 
of about 0.86 mg/l. Na2SO4 is added to the synthetic 
basal medium in an amount from about 0.35 to about 7.0 
mg/l, and most preferably in an amount of about 3.50 
mg/l. 
Growth supplements are also included in the present 
invention. According to the most preferred embodi 
ment, the growth supplement includes: delipidized bo 
vine serum albumin (BSA), insulin, transferrin, epider 
mal growth factor, glutamine, phosphoethanolamine, 
ethanolamine, a broad spectrum antibiotic, and a corti 
costeroid. The individual constituents of the growth 
supplement may be added to the synthetic basal medium 
separately or together after mixing. Regardless of how 
they are added, the amount of each growth supplement 
constituent added to 1000 ml of the synthetic basal 
medium is according to one preferred embodiment, as 
follows: from about 0.50 to about 2.3 grams of delipi 
dized BSA, and most preferably about 1.30 grams of 
delipidized BSA; from about 1.0 to about 10.0 mg of 
insulin, and most preferably about 5.0 mg of insulin; 
from about 2 to about 20.0 mg of transferrin, and most 
preferably about 10.0 mg transferrin; from about 50 mM 
to about 200 mM glutamine, and most preferably about 
120 mM of glutamine; from about 1.0 to about 11.2 mg 
of phosphoethanolamine, and most preferably about 5.6 
mg phosphoethanolamine; from about 0.24 to about 7.2 
mg of ethanolamine, and most preferably about 2.4 mg 
of ethanolamine; from about 1 to about 30 micrograms 
of epidermal growth factor, and most preferably about 
10 micrograms of epidermal growth factor; from about 
50,000 to about 1,000,000 units of penicillin, and most 
preferably about 100,000 units of penicillin; from about 
50,000 to about 1,000,000 of streptomycin, and most 
preferably about 100,000 units of streptomycin, and 
from 0.1 to about 5 mg of hydrocortisone, and most 
preferably about 1.0 mg of hydrocortisone. 
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The following examples are included to further de 
scribe the present invention and are not intended to 
limit the invention unless otherwise specifically indi 
cated herein. 
EXAMPLES 
A chemically defined, "high' calcium culture me 
dium was formulated to investigate the outgrowth and 
Subsequent long term maintenance or normal adult mu 
rine epidermal cells from explants of dorsal skin. In this 
investigation, the relative diameters of explants from 
normal skin were used together with the morphological 
appearance of the cultures at three weeks to evaluate 
several medium. Vitamins A and D, as well as linoleic 
acid were added separately or together to the SPRD 
110 medium at concentrations of 0.115 mg/1, 0.100 
mg/l, and 0.100 mg/l, respectively. Cutaneous explants 
of one square millimeter from medium treated with a 
supplement or control medium (SPRD-110 alone) all 
demonstrated epidermal outgrowth within one week. 
Some explants achieved diameters of seven millimeters 
by three weeks, and thereafter proliferated to conflu 
ence with concomitant terminal differentiation. 
Preparation of the Explants. Untreated female SSIN 
mice seven to nine weeks of age were sacrificed by 
cervical dislocation, dorsal hair clipped, and washed 
with Prepodine (American Sterilizer Co., Erie, PA) and 
70% ethanol in water. The dorsal skin was excised and 
placed in sterile calcium and magnesium free Dulbec 
co's phosphate-buffered saline. Each skin was removed 
to a sterile petri dish and every trace of subcutaneous fat 
and muscle removed by scraping with a scalpel. Pieces 
of one square mm were cut with a sharp scalpel and 
placed onto Corning tissue culture dishes previously 
coated with a collagen-fibronectin mixture according to 
Lechner, J. et al. In Vitro 18: 633-642, 1982 (10). Ap 
proximately ten minutes were allowed for the pieces to 
adhere to the dish before addition of the culture me 
dium. 
Culture Conditions. The explants were cultured in 
SPRD-1 i0 medium alone, SPRD-110 medium and 
0.115 mg/l retinyl acetate, SPRD-110 medium and 
0.100 mg/1 linoleic acid, SPRD-110 medium and 0.1 
mg/l ergocalciferol, or SPRD-110 medium and 0.115 
mg/l retinyl acetate, 0.100 mg/l linoleic acid, and 0.1 
mg/l ergocalciferol. Retinyl acetate was obtained from 
GIBCO, Grand Island, NY. Linoleic acid was obtained 
as linoleic acid conjugated bovine serum albumin from 
Sigma Chemical Company, St. Louis, MO. Ergocalcif 
erol was obtained from Sigma Chemical Company, St. 
Louis, MO. SPRD-110 medium is a "high" calcium, 
chemically defined medium previously developed by 
the present inventor to support long-term primary cul 
tures of adult murine epidermal cells under conditions 
permissive of both proliferation and terminal differenti 
ation (1). The formula of SPRD-110 may be described 
as follows: SPRD-10 is a modified MCDB-151 me 
dium supplemented by the addition of (suppliers given 
as examples): 
a) 20 ml/ MEMAAS; 
b) 10 ml/ MEMVS; 
c) 0 ml/ trace element supplement, prepared according 
to McKeehan, WL. et al., En Vitro 3:399-416, 1977: 
d) 1.30 grams/ of delipidized bovine serum albumin 
(Sigma); 
e) 5.0 mg/l of insulin (bovine: Sigma I-6634); 














g) 5.6 mg/1 of phosphoethanolamine (Sigma P-0503); 
h) 2.45 mg/l of ethanolamine (Sigma E-9508); 
i) 10 mg/l of transferrin (human: Sigma T-1147); 
j) 100,000 units/ of penicillin (GiBCO); 
k) 100,000 units/1 of streptomycin (Whittaker); 
1) 1 mg/l of hydrocortisone (Sigma H-0888); 
m) 130.81 mg/l of CaCl2: 
n) 0.417 mg/l of FeSO4.7H2O, 
o) 122.0 mg/l of MgCl2.6H2O; 
p) 0.863 mg/1 ZnSO4.7H2O, 
q) 3.51 mg/Na2SO4; and 
r) enough distilled H2O to make a final volume of 1135 
n. 
All cutaneous explants from adult mice were estab 
lished on dishes coated with Vitrogen-fibronectin (10). 
This coating had been shown to be important for estab 
lishing and maintaining cultures of freshly harvested 
adult murine epidermal cells (1). The explants were 
incubated at 36 C. in an atmosphere of 5% CO2 and 
95% air. The medium was changed twice weekly begin 
ing three days after the explants were prepared. As 
appropriate, the cultures were treated at each medium 
change with SPRD-110 medium alone, with SPRD-110 
medium and retinyl acetate (0.115 mg/l; GIBCO, 
Grand Island, NY), with SPRD-110 medium and lin 
oleic acid conjugated bovine serum albumin (0.100 mg/l 
linoleic acid; Sigma Chemical Company, St. Louis, 
MO), with SPRD-110 medium and ergocalciferol 
(0.100 mg/l; Sigma Chemical Company, St. Louis, 
MO), or with SPRD-110 medium and retinyl acetate 
0.115 mg/l, linoleic acid 0.001 g/l, and ergocalciferol 
0.100 g/l. After three weeks, the cultures were fixed 
with formalin, stained with Rhodamine B, and the diam 
eters of the explants measured. The diameter of each 
explant was calculated from measurement in two di 
mensions. Statistical significance was determined by 
Student's t Test. Other cultures were prepared for light 
and electron microscopy (1). 
Results. Regardless of the medium, by four days in 
vitro, epidermal outgrowth had usually begun in many 
of the explants and was present in most by seven days. 
Many mitotic figures were present in the radially ad 
vancing outgrowth. Although some stratification ac 
companied the advancing outgrowth, it was greatest in 
the regions closest to the explant itself. Electron Mi 
croscopy of the epithelial outgrowth disclosed many of 
the typical morphological characteristics of proliferat 
ing and differentiating epidermal cells in vivo including: 
basal cells with mitochondria, ribosomes, microtubules, 
desmosomes, and numerous keratin bundles throughout 
the cytoplasm. The proliferative layer was overlayed by 
a variable number of differentiating cells of which the 
most superficial demonstrate keratohyalin granules, 
nuclear degeneration, and cornified envelopes. 
The diameters of the explants were recorded at three 
weeks and the morphology of the cultures was studied 
using an electron microscope morphological character 
istics, such as, shape, size, and adherence were re 
corded. These results are summarized in Table I. 
TABLE I 
Effects of RetinylAcetate, Calciferol and 
Linoleic Acid on Adult Murine Epidermal Outgrowth" 
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Cutaneous explants from untreated adult mice were established on dishes coated 
with Vitrogen fibronectin, cultured for three weeks in supplemented or unsupple 
mented SPRD-10 Inedium, fixed in formalin, stained, and measured. 
Total number of explants measured in three to four separate experiments. 
Average S.D. 
values are significantly larger than that of SPRD-110 medium alone (p 0.0001 by 
Student's test). Favorable morphological considerations include uniformly compact, polygonal 
proliferative cells with slightly rounded rather than flat appearance. Differentiated 
cells are flat and platelike, and generally adherent to the proliferating cells. 
The relative abundance of mitotic figures in the epithelial outgrowth after two 
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The addition of the retinyl acetate alone to SPRD 
110 medium nearly doubled the explant diameter. Light 
microscopy confirmed that this increase was due pri 
marily to an increase in the number of proliferative cells 
rather than to a increase in the relative size of the cells. 
Although the addition of linoleic acid alone to SPRD 
110 medium did not increase the size of the epidermal 
outgrowths, its addition resulted in an apparent increase 
in the longevity of the cultures. Longevity was deter 
mined by the relative abundance of mitotic figures in 
the epithelial outgrowth after two weeks, and eventual 
proliferation to confluence. The addition of ergocalcif. 
erol (Vitamin D2) alone to SPRD-1 10 medium resulted 
in an improved morphology and uniformity of the epi 
dermal outgrowth rather than in an increased diameter 
of the explants. The addition of all three of the supple 
ments to the SPRD-110 medium nearly doubled the 
explant diameter and improved morphology and lon 
gevity beyond what was observed in trials using the 
supplements separately. Moreover, epidermal out 
growth from explants cultured in this formulation grew 
to confluence by seven to nine weeks, this was not 
observed in any other medium. 
Thus, on the basis of the data set forth above, the 50 
present inventor has demonstrated that the addition of 
retinyl acetate, ergocalciferol, and linoleic acid to a 
synthetic basal medium, surprinsingly and unexpectedly 
resulted in improved epithelial cell morphology, prolif. 
eration, differentiation and longevity. 
Changes obvious to those skilled in the art may be 
made in the various components, steps and procedures 
described herein without departing from the concept 
and scope of the invention as defined in the following 
claims. 
The citations in the following list are incorporated by 
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What is claimed is: 
1. A high calcium chemically defined animal cell 
culture medium, including: 
(a) SPRD-110 synthetic basal medium; 
(b) retinoid at a concentration of from about 0.01 to 
bout 1.0 mg/1; 
(c) vitamin D at a concentration of from about 0.01 to 
about 0.5 mg/1; 
(d) linoleic acid or its ester at a concentration of from 
about 0.01 mg/l to about 1 mg/l; and 
(e) calcium at a concentration of from about 0.1 nM 
to about 1.4 nM. 
2. The culture medium of claim 1, wherein the reti 
noid is one or more of retinyl acetate, retinol, retinal, 
retinoic acid, and retinyl palmitate. 
3. The culture medium of claim 1, wherein the reti 
noid is retinyl acetate. 
4. The culture medium of claim 1, wherein the vita 
min D is a reduction product of vitamin D2, dihydro 
tachysterol. w 
5. The cell culture medium of claim 3, wherein the 
retinyl acetate is present at a concentration of about 
0.115 mg/1. 
6. The cell culture medium of claim 1, wherein the 
vitamin D is vitamin D2, and is present at a concentra 
tion of 0.100 mg/1. 
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7. The cell culture medium of claim 1, wherein the 
linoleic acid is present at a concentration of about 0.100 
mg/l. 
8. The culture medium of claim 1, wherein the cal 
cium is present at a concentration of about 1.2 mM. 
9. A high calcium chemically defined animal cell 
culture medium, including: 
(a) a SPRD-110 synthetic basal medium; 
(b) retinyl acetate at a concentration of from about 
0.01 to about 1.0 mg/l; 
(c) ergocalciferol at a concentration of from about 
0.01 to about 0.5 mg/l; 
(d) linoleic acid at a concentration of from about 0.01 
mg to about 1.0 mg/l; and 
(e) calcium at a concentration from about 0.1 mM to 
about 1.4 mM. 
10. The culture medium of claim 9, wherein the reti 
nyl acetate is present at a concentration of about 0.115 
mg/l. 
11. The culture medium of claim 9, wherein the ergo 
calciferol is present at a concentration of about 0.100 
mg/l. 
12. The culture medium of claim 9, wherein the lin 
oleic acid is present at a concentration of about 0.100 
mg/l. 
13. The culture medium of claim 9, wherein the cal 
cium is present at a concentration of about 1.2 mM. 
14. A method for preparing a tissue culture medium 
high in calcium and suitable for the primary culture of 
epidermal cells comprising mixing together the follow 
1ng: 
(a) SPRD-110 synthetic basal medium; 
(b) retinoid at a concentration of from about 0.01 to 
about 1.0 mg/l; 
(c) vitamin D at a concentration of from about 0.01 to 
about 0.5 mg/l; 
(d) linoleic acid or its ester at a concentration of from 













(e) calcium at a concentration of from about 0.1 mM 
to about 1.4 mM. 
15. The method of claim 14 wherein the retinoid is 
one or more of retinyl acetate, retinol, retinal, retinoic 
acid, and retinyl palmitate. 
16. The method of claim 14 wherein the retinoid is 
retinyl acetate. 
17. The method of claim 14 wherein the vitamin D is 
a reduction product of vitamin D2, dihydrotachysterol. 
18. The method of claim 16 wherein the retinyl ace 
tate is present at a concentration of about 0.115 mg/l. 
19. The method of claim 14 wherein the vitamin D is 
vitamin D2 and is present at a concentration of 0.100 
mg/1. 
20. The method of claim 14 wherein the linoleic acid 
present at a concentration of about 0.100 mg/1. 
21. The method of claim 14 wherein the calcium is 
present at a concentration of about 1.2 mM. 
22. A method for preparing a tissue culture medium 
high in calcium and suitable for the primary culture of 
epidermal cells comprising mixing together the follow 
1ng: 
(a) SPRD-110 synthetic basal medium; 
(b) retinyl acetate at a concentration of from about 
0.01 to about 1.0 mg/l; 
(c) ergocalciferol at a concentration of from about 
0.01 to about 0.4 mg/l; 
(d) linoleic acid at a concentration of from 0.01 mg to 
about 1.0 mg/l; and 
(e) calcium at a concentration of from about 0.1 mM 
to about 1.4 mM. 
23. The method of claim 22 wherein the retinyl ace 
tate is present at a concentration of about 0.115 mg/l. 
24. The method of claim 22 wherein the ergocalcif 
erol is present at a concentration of about 0.100 mg/l. 
25. The method of claim 22 wherein the linoleic acid 
is present at a concentration of about 0.100 mg/l. 
26. The method of claim 22 wherein the calcium is 
present at a concentration of about 1.2 mM. 
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